Paying subjects for their research participation engenders quite a lot of discussion, both among research teams and on the IRB. The Food and Drug Administration (FDA) recently released an information sheet regarding its current thinking on paying subjects. The FDA, like the UAMS IRB, feels that payment should accrue as the subject progresses through the study and shouldn’t be contingent on study completion. However, the FDA and the UAMS IRB agree that paying a small proportion of the total amount at the end of a study is allowable. Please read the entire information sheet at the link above for a refresher on considerations related to payment.